Literature DB >> 8821609

Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria.

P L Chiodini1, C P Conlon, D B Hutchinson, J A Farquhar, A P Hall, T E Peto, H Birley, D A Warrell.   

Abstract

The activity of atovaquone in patients with oligosymptomatic Plasmodium falciparum malaria was assessed in an open, non-comparative clinical study. The patients showed a good clinical response, but there was a high rate of recrudescence. The activity of atovaquone in combination with another antimalarial agent should be investigated.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8821609     DOI： 10.1093/jac/36.6.1073

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  23 in total

Review 1.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Molecular characterization of the cytochrome b gene and in vitro atovaquone susceptibility of Plasmodium falciparum isolates from Kenya.

Authors:  Luicer A Ingasia; Hoseah M Akala; Mabel O Imbuga; Benjamin H Opot; Fredrick L Eyase; Jacob D Johnson; Wallace D Bulimo; Edwin Kamau
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

3.  Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reports.

Authors:  Gilles Cottrell; Lise Musset; Véronique Hubert; Jacques Le Bras; Jérôme Clain
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Searching for new antimalarial therapeutics amongst known drugs.

Authors:  Jennifer L Weisman; Ally P Liou; Anang A Shelat; Fred E Cohen; R Kiplin Guy; Joseph L DeRisi
Journal:  Chem Biol Drug Des       Date:  2006-06       Impact factor: 2.817

Review 5.  Strategic use of antimalarial drugs that block falciparum malaria parasite transmission to mosquitoes to achieve local malaria elimination.

Authors:  Rashad Abdul-Ghani; John C Beier
Journal:  Parasitol Res       Date:  2014-09-04       Impact factor: 2.289

6.  Alternative oxidase inhibitors potentiate the activity of atovaquone against Plasmodium falciparum.

Authors:  A D Murphy; N Lang-Unnasch
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

7.  Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system.

Authors:  Michael W Mather; Elisabeth Darrouzet; Maria Valkova-Valchanova; Jason W Cooley; Michael T McIntosh; Fevzi Daldal; Akhil B Vaidya
Journal:  J Biol Chem       Date:  2005-05-24       Impact factor: 5.157

8.  Biguanide-atovaquone synergy against Plasmodium falciparum in vitro.

Authors:  K Jones; S A Ward
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene.

Authors:  Ana Afonso; Zoraima Neto; Helena Castro; Dinora Lopes; Ana C Alves; Ana M Tomás; Virgílio D Rosário
Journal:  Malar J       Date:  2010-05-21       Impact factor: 2.979

10.  Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.

Authors:  Colin J Sutherland; Matt Laundy; Nicholas Price; Martina Burke; Quinton L Fivelman; Geoffrey Pasvol; John L Klein; Peter L Chiodini
Journal:  Malar J       Date:  2008-11-20       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.